FY2025 EPS Estimates for Certara Decreased by Analyst

Certara, Inc. (NASDAQ:CERT - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Certara in a research note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.28 per share for the year, down from their previous estimate of $0.29. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2028 earnings at $0.44 EPS.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS.

A number of other equities analysts also recently commented on the company. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. KeyCorp increased their price target on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Morgan Stanley assumed coverage on shares of Certara in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. Finally, JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.71.

Certara Stock Down 3.6%

Shares of CERT traded down $0.41 during midday trading on Friday, reaching $11.09. 875,697 shares of the stock were exchanged, compared to its average volume of 1,469,092. The company has a market cap of $1.80 billion, a price-to-earnings ratio of 34.85 and a beta of 1.43. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. Certara has a 12-month low of $8.64 and a 12-month high of $16.93. The firm has a 50 day simple moving average of $11.46 and a 200-day simple moving average of $11.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CERT. Versant Capital Management Inc increased its stake in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Certara in the 1st quarter worth approximately $31,000. Wells Fargo & Company MN lifted its holdings in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Certara during the first quarter worth approximately $39,000. Finally, Johnson Financial Group Inc. bought a new stake in shares of Certara in the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.